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Chapter 1: Thesis Objective
4
1.1 KiCS project
The  Kids  Cancer  Sequencing  program  (KiCS)  is  a  translational  research
program  established at The Hospital for Sick Children (SickKids) in Toronto,
Canada.  The  program  aims  are  to  improve  the  diagnosis  and  therapeutic
options of paediatric cancer patients. The program enrolls patients with a newly
diagnosed childhood tumour  or  who  may  show signs  of  a  potential  cancer
susceptibility.  Patients  enrolled  in  the  program  have  one  of  the  following
attributes:  have  a  new  primary  or  relapsed  tumour,  have  a  genetic
predisposition for cancer, have a cancer with poor prognosis, or have a poor
response to conventional cancer therapies.
These patients undergo genomic sequencing using next generation sequencing
(NGS) technology and the resulting data is analyzed to better characterize the
tumour in an attempt to identify a unique “fingerprint.”  Information derived from
NGS analysis are subsequently used to find variants relevant to cancer etiology
and diagnosis, identify treatment options for each specific patient and  follow
the tumour’s response to treatment.
1.2 Research aims
The main objectives of this PhD thesis was to develop novel  bioinformatics
algorithms  for  the  detection  of  clinically  relevant  variants  from  the  RNA
Sequencing (RNA-Seq) data. Then to use this highly accurate approach on
tumors  of  childhood  cancer  patients,  enrolled  in  KiCS.  Finally,  to  create  a
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classification scheme that enables a non-specialist to interpret the functional
consequences of each somatic fusion variant.
The  project  was  divided  into  two  different  sub-projects,  each  attempting  to
answer  an  open  questions  in  transcriptomic  analysis  applied  to  precision
medicine oncology.
The  first  question  relates  to  the  accuracy  of  RNA  sequencing:  can  the
sensitivity  and  specificity  of  transcriptomic  data  improve  such  that  he  can
replace  standard  molecular  assays?.  The  production  of  an  accurate  and
complete  transcriptome makes  RNA-Seq an  ideal  approach to  improve  the
diagnosis  and  therapeutic  treatment  of  cancer  patients.  However,  even  if
clinicians could ‘read’ all of the transcripts of all the oncology patients on the
day  of  their  diagnosis,  they  would  still  have  the  massive  challenge  of
interpreting  the  results.  In  fact,  the  majority  of  current  bioinformatics  tools
achieve poor sensitivity and specificity for detecting non-canonical fusions or
cryptic splicing events. They may also  produce vast lists of putative fusions,
which do not subsequently validate or are found in normal controls.
Sub-project  1  involved  the  development  of  a  novel  software  package  for
detecting,  filtering,  validating  and  classifying  driver  oncogenic  chimeric
transcripts, to overcome the lack of sensitivity and specificity problem pf the
existing fusion detection approaches.
The second question relates to transcriptional abundance in cancer: how does
the  transcriptional  output  of  a  cancer  cell  change  as  it  acquires  somatic
mutations, becomes neoplastic, and ultimately metastasizes?. Transcriptional
amplification,  whereby  the  entire  transcriptome  of  a  cell  increases  in
expression, represents the direct effect of  somatic mutations in transcription
and  can  be  used  in  the  development  of  novel  therapeutic  strategies  for
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aggressive  tumours.  However,  knowledge  of  the  tumour  types  driven  by
transcriptional amplification, as well as identification of the genes mediating this
effect is relatively unknown. Currently there are  no software tool to accurately
measure the transcriptional  output of  a cancer,  in  vivo,  from heterogeneous
patient specimens that have undergone RNA-Seq.
In  sub-project  2,  a  computational  method  to  measure  the  transcriptional
abundance  of  human  cancer  cells  from  primary  tumours  was  created  to
catalogue  the  rules  governing  how  somatic  mutation  exerts  direct
transcriptional effects. Results for this project were published on Cell Reports in
20161 
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Chapter 2: Fusion Validator: Highly accurate
fusion gene detection from RNA sequencing
of cancer
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2.1 Introduction
2.1.1 Gene fusions detection as a diagnostic test in clinical oncology
Accumulation of specific genomic aberrations like single nucleotide mutations
and  chromosomal  structural  rearrangement  are  a  major  cause  of  cancer
development2.  Chromosomal  rearrangements,  including  genomic  deletions,
duplications, inversions and translocations can lead to the formation of a fusion
of  two  genes,  that  would  otherwise  be  physically  separated.  This  resulting
fusion is exclusively expressed in cancer cells3 (Figure 1).
Recurrent gene fusions like BCR–ABL1 in chronic myeloid leukemia4, EWSR1-
FLI1  in  Ewing’s  sarcoma5,  EML4-ALK  in  lung  cancer6 or  FGFR-TACC  in
glioblastoma7, are considered strong driver mutations and used as diagnostic
markers or for therapeutic decision-making (Figure 2).
9
Figure  1.  Schematic  representation  of  a  gene  fusion  from  genomic  rearrangements
between different chromosomes (A) or same chromosome (B). In genomic rearrangements
between different chromosomes (A) genes from different chromosomes have a translocation on
the  breakpoint  position  (vertical  black  line)  and  form  a  fusion  gene.  The  product  of  the
translocation is transcribed into a fusion transcript containing exons from gene 1 (blue) and
from gene 2 (red). Rearrangement in the same chromosome (B) can be classified as deletion
(when a part of chromosome is lost during replication), inversion (when a part of chromosome
is reversed end to end) or eversion (when a part of chromosome is reversed end to beginning)
and are transcribed into fusion transcripts containing exons from gene 1 (blue) and from gene 2
(green)   
10
A
B
Figure 2.  List  of  most  recurrent gene fusions in different  cancer types according to
Parker et al. [Parker]
The advent of NGS platforms and the use of RNA-Seq paired-end technique in
tumour  studies  allowed the  identification  of  an  increasing  number  of  fusion
transcripts collected in public databases8,9 (Figure 3).
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Figure 3. Timeline showing the years in which particular driver fusions were discovered, 
compared to the year in which DNA sequencing technologies became available. (Figure 
from Parker et al. [Parker])
The ability  to  characterize the  entire  transcriptomic  profile  in  a  precise and
efficient way, at reduced cost compared to traditional techniques, and with the
power  to  uncover  novel  events  in  a  single  test,  makes  RNA-Seq  fusion
detection a very suitable and attractive instrument to improve the diagnosis and
therapeutic  treatment  of  cancer  patients10.  In  the  last  few  years,  different
institutes have established personalized cancer medicine programs giving rise
to what  is called precision oncology11.  Some institutes have included fusion
transcripts in their investigation of biological driver events12,13.
Regardless  of  the  integration  of  NGS diagnostic  tests  within  time and cost
budgets, significant challenges for clinical interpretation exist. First, algorithms
used to detect any targetable genomic alteration must be robust and have the
ability  to  detect  a wider  range of  variants with  high sensitivity  compared to
12
available methods.  Several  experimental  design  components,  like  sequence
length, coverage and the choice of appropriate library preparation protocols,
should  be  also  taken  in  consideration  before  sequencing,  to  avoid  missing
biologically  relevant  events.  Second,  the  list  of  putative  candidate  variants
detected can contain false positive calls, due to technological and biological
biases in NGS data, and this decrease the specificity.  Correctly filtering out
chimeric  events  is  crucial  to  reduce  the  number  of  candidate  variants  to
investigate.  Third,  the  genetic  variants  discovered  can  include  events  not
present in any database or appearing in only a single patient, may produce
fusions between adjacent genes in the genome (read through), or alterations
observed  in  normal  tissues14-15.  Therefore,  a  very  accurate  annotation  and
validation of results is required to best select candidate oncogenic variants16.
Some  of  the  approaches  used  to  confirm  RNA-Seq  variants  like  Sanger
sequencing or real time PCR assay17 are time consuming and labor intensive,
making the validation of a large number of transcriptomic event candidates  not
feasible. The demand of a robust analytical validation on customizable panel of
gene fusion at affordable costs, and with low RNA input requirements, has led
different  groups  to  use  targeted  RNA deep  sequencing  as  a  NGS  based
diagnostic test in clinical oncology18-19.
2.1.2 Different approaches for gene fusion detection in RNA-Seq Experiments
To partially resolve gaps in RNA-Seq fusion transcripts analysis, several new
software tools have been developed over the past few years. These tools differ
each other by reads alignment strategies, fusion prediction algorithms, and/or
filtering criteria used16,20,21 (Table 1).
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Table  1.  List  of  fusion detection  bioinformatic  software  developed in  the  past  years
(Figure from Davare et al.16).
Carrara  et  al.22 classified  fusion  detection  tools  according  to  alignment
strategies:  Softwares  like  deFuse23,  Fusionseq24,  FusionHunter25,  Ericscript26
and SOAPfuse27 align paired-end reads to a reference sequence and create a
set of putative fusion products using discordant alignments (Whole paired-end
approach  Figure  4).  Other  tools  like  MapSplice28,  FusionFinder29 and
FusionMap30 fragment  reads  into  smaller  segments  and  try  to  find  fusion
candidates  aligning  these  fragments  against  the  reference  (Direct
fragmentation approach Figure 5). Another strategy that combines both paired-
end and fragment alignment is used by ChimeraScan31, Bellerophontes32 and
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Tophat-Fusion33.  Using  this  two-step  approach,  reads  are  first  aligned  as
paired-end sequences against the reference to detect putative fusion products
via discordant alignments. Reads that remain unaligned after first step are then
fragmented  and  realigned  to  identify  junction-spanning  reads  of  the  fusion
transcript21 (Figure 6).
Figure 4. Whole Paired-end fusion detection approach.
In  the  whole  paired-end  approach,  sequences  are  aligned  to  the  reference  genome  and
transcriptome. The reads, in which each mate aligns to a different gene (discordant reads),  are
then used to select a list  of putative fusion products. All the unmapped reads from the first
alignment step are then realigned locally to confirm each putative fusion product. (Figure from
Raffaele  Calogero’s  presentation  “Alternative  Splicing  Variants  and  Translocation  Induced
Chimera detection, strength and limits of state of the art  bioinformatics approaches). 
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Figure 5. Direct fragmentation fusion detection approach.
In the direct fragmentation approach, sequences are fragmented into small segments of a user
defined size and then aligned to the reference. Discordant aligned mate pairs are then used to
find  potential  candidate  fusions.  (Figure  from Raffaele  Calogero’s  presentation  “Alternative
Splicing Variants and Translocation Induced Chimera detection, strength and limits of state of
the art bioinformatics approaches).   
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Figure 6. Paired-end + fragmentation fusion detection approach.
In the paired-ends + fragmentation approach the reads are first aligned in paired-ends against
the reference to detect putative fusion products via discordant alignments. Then sequences
unaligned at first step are fragmented and realigned to identify junction-spanning reads of the
fusion transcript. (Figure from Raffaele Calogero’s presentation “Alternative Splicing Variants
and  Translocation  Induced  Chimera  detection,  strength  and  limits  of  state  of  the  art
bioinformatics approaches). 
Performance evaluation of different computational methods for gene fusion 
discovery, on both real and simulated datasets, revealed a consistently high 
number of false positive events and very little overlap between different tools22-
34.
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Due to heterogeneous results and different sensitivity in identifying chimeras, a
combination  of  various  fusion  finder  tools  was  suggested  to  compensate
individual tool errors and correctly detect driver fusions in cancer patients35.
This combination can lead to the identification of thousands of different fusion
transcripts,  most  of  them  false  positives,  that  reduce  the  specificity  and
increase the complexity of downstream analysis and experimental validation.
The  false  positive  rate  can  be  partially  reduced  using  filtering  steps
implemented on fusion finder algorithms, but the number of events that require
a  biological  confirmation  still  remains  high.  Most  common  filtering  options
among different fusion detection tools includes the removal of:
 read-through transcripts
 candidate fusion mapping on homologous and repetitive regions
 PCR artifacts
 transcripts supported by poor read quality, read pair distance, number of
spanning-junctions  supporting  sequences  and  number  of  nucleotides
overlapping each side of the fusions breakpoint.
Other  filtering  steps  are  software-specific,  like  the  comparison  between
chimeric transcript expression and the corresponding genes expression, used
by  FusionSeq,  or  the  option  to  select  only  canonical  or  semi-canonical
junctions,  used by  MapSplice.  Many fusion  detection  programs also  accept
user  provided  blacklists  of  gene  fusions  found  in  normal  tissues,  or  from
existing  fusion  transcript  databases.  However,  this  filtering  procedure  can
introduce  additional  errors,  since  the  detection  of  gene  fusions  in  normal
datasets  may  encounter  the  same  software-dependent  sensitivity  and
specificity biases found in tumour samples36.
Moreover, only few bioinformatics softwares can currently annotate, filter and
prioritize  fusion  transcripts  detected  by  multiple  algorithms.  The  Chimera  R
package from Beccuti et al.37 can manipulate outputs from 12 different fusion
detection softwares and includes a breakpoint  validation feature through de
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novo assembly of reads. However, Chimera encounters issues in summarizing
identical fusion genes picked by different fusion finder algorithms, especially
when fusions involve genes overlapping  each other on the opposite strands or
results from tools that use different transcriptome annotations are compared.
Fusion Matcher (FuMa)38 was designed to improve Chimera’s functionality by
comparing  and  matching  fusion  genes  coming  from  different  fusion  finder
algorithms, and  using a unique and consistent annotation to easily summarize
identical fusions. Other fusion annotation tools try to predict oncogenic potential
of fusion genes using machine learning algorithms. Oncofuse39 for example,
uses a naive Bayes Network classifier, trained on features present in known
oncogenic fusions, to predict the probability of a novel chimera to be classified
as a  driver  fusion.  This  machine learning  classifier  takes into  consideration
protein  domains  maintained  in  fusion  transcripts,  but  ignores  interactions
between  functional  protein  domains.  For  this  reason,  recently  Abate  et  al.
developed  Pegasus40,  a  functional  annotation  software  that  identifies  the
fusion’s  reading  frame  and  conserved/lost  protein  domains  for  each
reconstructed chimeric transcript sequence. Pegasus then uses this information
to train a classifier based on a gradient tree boosting algorithm, in order to
predict  fusion  oncogenic  potential.  At  present  Pegasus takes  in  input  gene
fusion candidates from 3 different fusion finder algorithms, requiring the users
to  format  results  from  other  fusion  detection  tools  into  a  common  general
format.
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2.1.3 Project aim
The aim of sub-project 1 is to create a bioinformatics pipeline to address the
major  challenges  in  the  clinical  validation  of  fusion  transcripts  from  NGS
experiments.  This  will  be  achieved by  increasing  the  performance of  driver
fusions detection and by significantly reducing the number of false positives. To
address these challenges, we developed Fusion Validator, a tool able to scan
and filter a multitude of fusion genes from different fusion finder algorithms, and
to validate real events through chimeric transcript sequence reconstruction and
local realignment of candidate reads around fusion breakpoint.
Fusion Validator’s main features are unique and yield improved results over
current  methods.   First,  the  pipeline  is  completely  algorithm agnostic,  as  it
accepts  input  lists  of  chimeric  transcripts  detected  by  most  of  currently
available  fusion  detection  tools,  and  converts  the  results  into  a generic  file
format for further processing. The user then has the opportunity to select the
most suitable combination of programs to use for optimal sensitivity.
Second,  Fusion  Validator  uses  the  input  list  of  chimeric  transcripts  to
reconstruct the sequence spanning the fusion between two different genes or
between two internally rearranged genes. It is designed to work with canonical
fusions as well as other somatic structural changes in the transcriptome, like
exon skips.  Fusion Validator is also able to remove recurrent transcripts that
are  found  in  normal  transcriptomes,  through  dynamic  alignment  of  normal
sequences around the breakpoint of aberrant transcripts. This procedure gives
the user the opportunity to select a list of thousands of RNA-Seq experiments
on  a  large  number  of  diverse  human  tissues  from  the  Genotype-Tissue
Expression (GTEx) project41 or GEUVADIS42, and efficiently remove recurrent
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false  positive  events,  directly  comparing  putative  junctions  against  a  multi-
tissue dataset, instead of processing the tumour and normals separately. 
The  dynamic  local  realignment  approach  is  also  used  to  validate  the
breakpoints  of  the  chimeric  transcripts  and  additional  filtering  steps  are
performed to significantly reduce the number of fusion candidates and increase
the software’s specificity. Lastly, Fusion Validator is able to annotate and assign
a score to each chimeric transcript,  empowering the user with the ability  to
rank the final validated list of fusions and quickly distinguish driver fusions for
further investigation.  The Fusion Validator workflow is completely automated
and allows the user to  merge,  filter  and validate thousands of  fusions from
different  detection  tools,  without  any  additional  work  and  in  a  significantly
reduced computational time, using a high performance computer cluster.
2.2 Material and methods
2.2.1 Simulated datasets
EricScript Simulator tool (Eric Script 0.5.4) was used to simulate 1000 synthetic
gene fusions with breakpoints randomly chosen among all known splicing sites
of involved genes (Intact exons (IE)), and the same 1000 fusion events with
breakpoints  randomly  chosen  without  taking  in  consideration  splicing  sites
(Broken exons (BE)). For each dataset of BE and IE fusions, approximately 13
million synthetic 125 base pair (bp) paired-end supporting reads were created.
The average insert size for simulated reads was 400bp, with 50 bp standard
deviation. 
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An additional 10 million 125bp paired-end reads were randomly generated as
background noise using the BEERS simulator43. Synthetic reads generated with
EricScript and BEERS were merged to create two starting simulated datasets:
one for BE fusions and one for IE fusions.
Additional synthetic datasets containing reads of different lengths (50bp, 75bp,
100bp, 125bp) and a range of sequencing coverage (25X, 50X, 100X, 200X,
300X and 400X) were created by randomly subsampling the starting set  of
reads,  using FASTX-Toolkit  (http://hannonlab.cshl.edu/fastx_toolkit/index.html)
and seqtk (https://github.com/lh3/seqtk).  Thus creating a total  of 24 different
datasets with BE and 24 with IE (Figure 7) (Table 2). To ensure read quality
consistency between every dataset, a Phred quality score of 25 was manually
assigned to all the bases of the simulated reads generated. 
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Figure  7.  Simulated  fusion  datasets  selection  steps.  1000  random  in  silico  chimeric
transcripts  were  extracted  from  human  genome  and  gene  models,  together  with  reads
supporting each specific transcript, for a total of 48 datasets of sequences with different length
(50, 75, 100, 125 base pair), sequencing coverage (25X, 50X, 100X, 200X, 300X, 400X), and
breakpoint positions (on a exon junction for intact exons or random for broken exons).
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Table 2. Number of reads supporting fusions and background reads extracted for each
simulated dataset.
2.2.2 Breast Cancer Cell lines
The second dataset used for validation was from RNA-Seq  of 4 Breast Cancer 
(BRCA) cell lines (BT-474, SK-BR-3, KPL-4 and MCF-7) containing  27 gene 
fusions that had already been validated44 were downloaded from NCBI 
Sequence Read Archive (SRA accession number SRP003186) (Table 3).
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Table 3. List of fusion genes validated by Edgren et al. In 4 BRCA cell lines.
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2.2.3 The Cancer Genome Atlas pan-cancer dataset
Finally we used additional 50bp fastq sequences from 190 pan-cancer samples
from The  Cancer  Genome Atlas  (TCGA)45 were  downloaded  from the  NIH
Genomic Data Commons (GDC) Data Portal [http://gdc.nci.nih.gov/], along with
their respective lists of  195 recurrent fusions involving kinases (115 unique)
validated by Stransky et al46 (Table 4).
26
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Table 4. List of recurrent kinase fusions validated by Stransky et al. In 190 pan cancer
TCGA samples.
2.2.4 Normal tissue control dataset
We obtained control  transcriptomes derived from the non-diseased tissue of
healthy individuals from the NHGRI GTEx consortium (database version 4).
Representative samples  for  each tissue and sub-tissue type were selected.
Samples were ordered by RNA Integrity Number (RIN) in descending order and
by the time with which samples were prepared after the patients decease in
ascending  order.  We  excluded  samples  for  which  the  autolysis  score  was
greater than 2. Up to 30 samples for each tissue type were then selected from
the sorted list, for a total of 1277 samples from 43 different tissues (Table 5).  
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Table 5. List of GTEX samples used for Fusion Validator’s normal filtering step stratified
by tissue and subtissue.
2.3 Analysis
2.3.1 Fusion detection analysis
Fusion transcripts for both simulated dataset and BRCA cell lines test set were
detected  using  Defuse  0.6.2,  Chimerascan  0.4.5,  STAR-fusion  0.7.047,
MapSplice  2.1.9  and  FusionCatcher  0.99.4d_beta48 with  default  parameters
and no filtering options activated. Defuse, Chimerascan and STAR-fusion were
also selected to  find  gene fusion candidates  on TCGA pan-cancer  dataset.
Gencode Release 19 (GRCh37.p13) was used as reference gene model for all
the alignments.
2.3.2 Statistical analysis
Fusion  genes randomly  selected  in  simulated dataset  were  validated using
Fusion  Validator.  Positive  Predicted  Value  (PPV),  sensitivity,  specificity,
accuracy and F-Measure were used to assess the performance of the novel
tool. PPV is defined as the proportion of true positive fusions divided by the
positive calls. Sensitivity is computed as the ratio between true positives events
and the sum of true positives and false negatives, while specificity correspond
to the ratio between true negatives and the sum of true negatives and false
positives.  Accuracy  represent  the  proportion  of  true  calls  (positives  and
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negatives) on the total  number of  calls and F Measure is calculated as the
harmonic mean of PPV and Sensitivity.  
2.4 Fusion Validator workflow
The Fusion Validator workflow consists of 4 different components (Figure 8):
Step  1)  Integration  of  different  fusion  detection  tools  and  reconstruction  of
chimeric transcripts.
Step 2) Removal of non-cancer fusions through local realignment of sequences
from normal tissues on chimeric transcripts.
Step 3) Validation of fusion transcripts through local realignment and de novo
assembly of tumour reads.
Step 4) Annotation of fusions transcripts and ranking score assignment.
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Figure 8. Fusion Validator workflow. 
Step 1: Chimeric transcript breakpoint coordinates from several fusions or alternative splicing  
detection software are merged and annotated using a standardized file format. Each chimeric 
transcript sequence around the breakpoint is subsequently reconstructed   by extracting a user 
defined region length upstream and downstream from the fusion breakpoint.
Step 2: Sequences from user-provided list of normal samples are locally realigned against each
candidate chimeric transcript to remove aberrant junctions present in normal tissues. A blacklist
with the coordinates of each event removed by normal filter is dynamically populated whenever 
a new sample is processed.   
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Step 3: Reads from the tumour sample are locally realigned against each detected and filtered  
chimeric transcript to select sequences spanning the breakpoint as potential candidates to 
reconstruct the fusion/skip.
Validation of the breakpoint is performed using the candidate reads and combining both a de 
novo assembly and a seed and extend algorithm for scaffold closing.
Additional filtering options are included to remove fusions mapping on homologous or highly 
repetitive regions. 
Step 4: Chimeric transcripts retained after the validation step are annotated and a ranking 
score based on a linear combination of predictor variables is calculated for each event.
    
2.4.1 Integration of chimeric transcripts detected from multiple tools
The first  component  of  Fusion  Validator  creates  a  framework  that  converts
results  from  different  fusion  detection  software  into  a  generic  file  format,
generating  a  list  of  aberrant  transcript  junction  sequences  for  further
processing.  First, Fusion Validator collects basic fusion information, like gene
names,  breakpoint  coordinates  and  the  number  of  reads  supporting  the
chimeric event from different fusion or alternative splicing detection tools. A set
of  different  modules  are  then  used  to  extract  additional  chimeric  transcript
information from a user defined gene model GTF file, to create a consensus
multi  tool  output  with  a  standard  annotation:  The  annotation  includes
coordinates and strand of the genes that create the chimeric transcript, splice-
donor  and  splice-acceptor  site,  gene  location  and  exonic  location  of  the
breakpoints. During the first step, a preliminary optional screening of the fusion
transcripts  is  also  performed  to  remove  read  through  events,  fusions/skips
involving miRNAs, small nucleolar RNAs, ribosomal and mitochondrial genes.
Any fusion transcripts detected by more than one algorithm involving the same
genes with identical breakpoints and orientation, are collapsed into one single
record and noted as having been recurrently found by different software.
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After  this  initial  screening,  the  multi-tool  integration  step  reconstructs  each
chimeric transcript sequence around the breakpoints, extracting and merging a
region upstream from the fusion breakpoint for 5’ gene, and downstream from
the breakpoint for 3’ gene (default length 200bp). The chimeric sequence is
retrieved  at  the  genomic  level  for  breakpoints  falling  into  intronic  or
up/downstream regions and at transcriptomic level for exonic breakpoints. If an
exonic  breakpoint  overlaps  different  transcript  isoforms,  the  reconstruction
algorithm gives priority to transcripts whose breakpoint is on an exon junction,
and then to the longest length isoforms. Fusion Validator currently supports the
analysis of fusions detected by Defuse, Chimerascan, STAR-Fusion, TopHat-
Fusion, MapSplice, FusionCatcher and exons skips detected by Skippy. 
2.4.2 Normal tissues filter
The  second  component  of  Fusion  Validator  is  responsible  for  removing
recurrent transcripts that are also found in normal transcriptomes, using a user
provided list of sequences from RNA-seq of normal tissues. This filtering step
also makes use of a blacklist database of fusions already validated in normal
tissues, that is dynamically updated as well  as new samples are processed
through the Fusion Validator pipeline. The list of chimeric transcripts created
after the multi tool integration step is first scanned against the normal blacklist
to  remove all  the events already found in  normal  tissues and involving the
same genes with the same strands and breakpoint coordinates.
Then,  sequencing  reads  for  each  user  provided  normal  tissue  are  locally
aligned with  STAR 2.4.2a against  the  chimeric  transcripts  that  remain  after
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blacklist  screening.  Every  aligned  read  is  considered  as  a  candidate  for
supporting  the  fusion  in  a  normal  sample  if  it  spans  the  breakpoint  of  the
chimeric  transcript  with  a  perfect  match  and  with  a  minimum  overlap
(parameter -e, default = 10 bp). Every chimeric transcript containing a minimum
number of candidate reads (parameter -r , default = 3 reads) for more than 3
normal  tissues  (parameter  -n  ,  default  =  3  samples),  is  discarded  and  its
breakpoint  coordinates dynamically  populates the blacklist  normal database.
Remaining events not found in normal tissues are selected for further validation
in tumour samples.
Simulated normal filtering steps were run on fusions detected on 5 random
TCGA pan cancer samples of different sizes from Stransky et al., using subsets
with different number of Gtex normal tissue samples, to assess the relationship
between the number of normal samples screened versus the number of fusions
discarded by the normal filter. 
Results in Figure 9 show that the number of fusions removed by the normal
filter  rapidly  increases  when  up  to  250  normal  samples  are  used.  The
distribution curve tends to slightly increases when the list contains over 500
normals, and starts reaching a plateau at   approximately 1300 samples. This
amount of normal samples represents the optimal  configuration for  Fusion
Validator normal filtering module, since adding extra samples provides minimal
benefit  in  terms  of   normal  fusion  removal,  while  significantly  increasing
computational time.
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 Figure 9. Distribution of number of fusions removed by Fusion Validator normal filter
varying  the  number  of  GTEx  normal  tissues  used  for  5  different  pan-cancer  TCGA
samples. 
The  number  of  events  classified  as  present  in  normal  tissues  and  removed  by  Fusion
Validator’s normal filter tends to increase in each of the 5 TCGA samples processed  as the
number  of  GTEx  normal  tissues  used  increases.  The  distribution  curve  tends  to  slightly
increase when the list contains over 500 normals, until it reaches a plateau at around 1300
samples.
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2.4.3 Local realignment validation
The  third  component  of  Fusion  Validator  evaluates  chimeric  transcripts
candidates through a dynamic realignment approach, to distinguish real fusion
or  skip  events  from  artifacts.  RNA-seq  reads  from  the  tumour  are  locally
aligned in single end against each chimeric transcript retrieved in the previous
step, using STAR 2.4.2a. All the reads aligning on each chimeric transcript are
extracted using samtools and selected as potential  candidates to attempt to
reconstruct the sequence spanning the breakpoint and validate the fusion/skip.
Validation  of  the  breakpoint  is  performed  using  the  candidates  reads  and
combining  both  a  de  novo  assembly  and  a  seed and extend  algorithm for
scaffold closing (Figure 10). De novo assembly of candidate reads is performed
using  Abyss  1.9.049 with  iteration   steps  for  different  kmer  size.  Contigs
generated  by  Abyss  are  then  compared  with  the  reconstructed  chimeric
transcript using BLAST. Fusions/skips are considered validated if at least one
de novo assembled contig spans the breakpoint of the chimeric transcript, with
at least 3 bp overlap and with maximum 1 mismatch.
The second approach used for validating the aberrant transcripts creates an
artificial 5 base gap around the chimeric transcript breakpoint (the base on the
breakpoint and the 2 bases at 5’ and 3’ of the breakpoint are replaced with Ns),
and  uses  Gapfiller  software50 to  try  to  close  the  artificially  created  scaffold
between the two genes involved in a fusion, or the two exons involved in a skip.
In  brief,  reads  previously  selected  as  potential  candidates  for  chimeric
transcript reconstruction are used as input sequences for Gapfiller and aligned
against  the  artificial  scaffolds  for  each fusion/skip  using  Bowtie51 (for  reads
lower than 50 bp) or the Burrows-Wheeler Aligner (BWA)52 (for reads longer
than 50bp). Reads aligned on scaffold sequences are then split into shorter k-
mers and used to iteratively fill the created  gap, from the left and right edge,
one nucleotide at a time. The k-mer size is selected as 85% of the length of the
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reads; This size was tested on different Gapfiller runs on simulated and real
datasets  and  was  the  one  which  ensured  the  best  compromise  between
coverage and accuracy in gap closing. Every nucleotide incorporated step by
step by Gapfiller is considered to fill a base gap if is covered by at least 2 k-mer
sequences.  After filling all the gapped bases, the scaffold can be considered
closed and the chimeric transcript validated if an overlap of minimum 3 bp can
be found in both left and right extension and the difference between the final
length of the gapclosed sequence and the length of the original scaffold is not
higher than 1 bp. Chimeric transcripts successful reconstructed and confirmed
by de novo assembly or gap filling approach are flagged in the final output as
validated.     
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Figure 10. Schematic representation of chimeric transcript’s breakpoint validation.
Tumour reads are realigned in single end on each reconstructed chimeric transcript and only
sequences spanning the breakpoint are selected as candidate reads.
Using  a  de  novo  assembly  approach  (ABYSS),  a  contig  generated  by  candidate  reads
reassembly  is  eligible  to  validate  the  chimeric  transcript  if  it  spans  the  breakpoint  of  the
chimeric sequence, with at least 3 bp overlap and with maximum 1 mismatch.
Using a seed and extend alignment approach (Gapfiller), a chimeric transcript is validated if the
candidate reads can close and extend, for minimum 3bp in both 5’ and 3’ direction, an artificial
5bp scaffold around the chimeric sequence breakpoint.
2.4.4 Genomic realignment validation
Additional  filtering  options  are  included  only  for  fusion  genes  validation  to
remove  chimeric  transcripts  with  sequence  similarity  between  two  regions
around  the  breakpoint,  or  with  other  locations  in  the  genome,  as  well  as
transcripts with breakpoint located in highly repetitive regions (Figure 11). 
During  this  step,  previously  reconstructed  fusion  transcript  sequences  are
aligned  to  the  reference  genome using  BLAST,  with  DUST filtering  for  low
complexity regions activated.
 
Chimeric  transcripts  that  realign  in  genomic  regions  of  low  complexity  are
flagged  by  Fusion  Validator  as  “low  complexity  regions”.  Then,  for  every
analyzed transcript, if the sequence spanning the breakpoint aligns with more
than 50bp and with 100% identity to other locations in the genome, the chimeric
candidate  is  considered  as  a  misalignment  due  to  high  level  of  homology
between regions and reported by Fusion Validator with the flag “homologous
region”. As final step, for every BLAST alignment spanning the breakpoint of a
chimeric transcript, the difference between the end of the 5’ gene alignment
and the breakpoint position and the difference between the start  of  3’ gene
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alignment and the breakpoint position  is  computed. If the maximum of the two
differences is higher than 5 bases with identity greater than 99%, there is a
high similarity between the regions of the two genes surrounding the breakpoint
and the fusion transcript  is flagged as “similarity between genes” by Fusion
Validator.  The  genomic  realignment  filter  can  be  used  to  remove  fusions
involving  pseudogenes  or  solve  conflicts  between  genes  with  different
rearrangements (so called promiscuous genes).   
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Figure 11. Additional Fusion Validator filter based on sequence similarity on the genome.
Realignment of candidate fusion against the genome:
a)  Fusion candidate passing the genome realignment filter
b)  Fusion candidate with high similarity between the regions of the two genes surrounding the 
breakpoint
c)  Fusion candidate aligning in multiple regions with high level of homology.
2.4.5 Annotation and ranking
The last  component  of  Fusion  Validator  annotates  each  chimeric  transcript
retained after the validation step and calculates a score that is used to rank the
final list of validated events. The ranking score is the result of a function based
on a linear combination of predictor variables that best discriminate between
cancer-driver validated events and false positives. The predictor variables of
the  function  and  their  relative  coefficients  were  generated  using  a  linear
discriminant  analysis  function as a training set  on the 115 validated kinase
fusions from 191 pan-cancer TCGA samples described above.
  
The list of annotation variables used to compute the ranking score, summarized
in Table 6, are: 
- Total number of reads supporting the fusion: Include mate pairs that harbour a
fusion junction in the insert sequence (span reads) and pairs that harbour the
fusion junction in one of the two reads (split reads).
- Breakpoint coverage: Corresponds to the number of reads locally aligning on
the  region  5bp  upstream  from  the  fusion  breakpoint  for  5’  gene,  and  5bp
downstream from the breakpoint for 3’ gene of the chimeric transcript. Reads
that  are  not  a  primary  alignment  and  have  more  than  4  mismatches  are
excluded from counting.
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- 3’/5’ imbalance ratio: Is a measure of the read orientation distribution around
the fusion  transcript breakpoint and is calculated by subtracting the number of
3’ reads to the number of 5’ reads spanning the chimeric transcript breakpoint,
and dividing the result by the breakpoint coverage. 3’/5’ imbalance ratio range
from -1 (all the sequences spanning the breakpoint are 3’ reads) , to +1 (all the
sequences  spanning  the  breakpoint  are  5’  reads).   Values  closer  to  the
extremity of this interval are more likely to be artifacts caused by sequencing
errors.
- Gene location: The location of the breakpoints for both the genes involved in
the fusion. (intronic, up/downstream, exonic or coding sequence).
- Exonic location: The location of the breakpoint in the exons of the fusions
(inside, outside or at start or end of an exon).      
-  Fusion  recurrence  in  solid  tumours:  Annotation  step  check  if  the  genes
involved in the fusion are present  in the Catalogue Of Somatic  Mutation In
Cancer (COSMIC) [Forbes] fusion database version 77 for GRCh37.
-  Donor/acceptor  site:  The  splice  pattern  on  the  fusion  junction.  The  major
canonical splice pattern GT-AG is most likely to be preserved in true fusion
than the minor canonical ones (GC-AG and AT-AC) or the non-canonical (any
other combination of dinucleotides).
-  Number  of  different  fusion  finder  tools  that  have  identified  the  chimeric
transcript:  Recurrent  driver  events  are  usually  detected  by  multiple  fusion
detection software tools.
- Fusion orientation: Indicates the strand of the fusion junction for the first and
second gene involved in  the fusion.  Fusions with  both genes on the  same
orientation are most likely to be true.
-  Reading  frame:  Predicted  effect  of  the  fusion  estimated  using  Gene
Rearrangement  AnalySiS  (GRASS)  tool  [https://github.com/cancerit/grass].
Different reading frame predictions include frameshift fusions, in frame fusions,
stop  codon formed at  breakpoint  junction,  UTR to  UTR fusions,  intronic  or
ambiguous events. 
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-  Number  of  contigs  generated  by  de  novo  reconstruction  of  the  chimeric
transcript: A high number of contigs generated by de novo assembly is due to
the alignment of a large number of candidate reads with mismatches or multiple
alignments. High number of de novo contigs increase the probability of a fusion
transcript to be an artifact.
- Maximum percentage of chimeric transcript reconstructed by de novo aligned
contigs: It’s calculated for each chimeric transcript sequence as the length of
the longest de novo aligned contig spanning the breakpoint junction divided by
the  total  length  of  the  reference  chimeric  transcript.  A high  percentage  of
reconstructed chimeric  transcript  increases the  probability  of  a  fusion to  be
classified as a true positive event.   
-  Maximum overlap around the breakpoint for de novo aligned contigs: It  is
calculated as the maximum difference between the end of a contig and the
chimeric transcript breakpoint position, if the contig overlaps mostly on 5’ gene,
and  as  the  maximum  difference  between  the  start  of  a  contig  and  the
breakpoint  position,  in  the  opposite  case.  A  longer  overlap  around  the
breakpoint increases confidence in the validation of a fusion event.
- Maximum percentage of chimeric transcript reconstructed by de novo aligned
contigs: It’s calculated for each chimeric transcript sequence as the length of
the longest de novo aligned contig spanning the breakpoint junction divided by
the  total  length  of  the  reference  chimeric  transcript.  High  percentage  of
reconstructed  chimeric  transcript  increase  the  probability  of  a  fusion  to  be
classified as a true positive event.  
-  Maximum overlap around the breakpoint for de novo aligned contigs: It  is
calculated as the maximum difference between the end of a contig and the
chimeric transcript breakpoint position, if the contig overlap mostly on 5’ gene,
and  as  the  maximum  difference  between  the  start  of  a  contig  and  the
breakpoint position, in the opposite case. The longer is the overlap around the
breakpoint the more reliable is the validation of a fusion event
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Table 6. List of annotation variables used for ranking score prediction and relative  
categories.
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2.5 Determining the accuracy of Fusion Validator using 
simulated datasets 
2.5.1 Established fusion detection tools perform differently in simulated 
datasets
The performance of Fusion Validator in terms of sensitivity and PPV, compared
to other fusion detection software, was assessed using a total of 48 simulated
datasets with different coverages (25X, 50X, 100X, 200X, 300X and 400X),
read lengths (50bp, 75bp, 100bp and 125bp) and breakpoint positions (intact or
broken exons). Our comparison of different fusion detection tools demonstrated
that most had widely varying performance for different breakpoint position. The
only exception was defuse, which had an average sensitivity of 95.97% for IE
and 96.45% for BE and an average PPV of 40.95% for IE and 41.57% for BE.
FusionCatcher,  Mapsplice  and  STAR-fusion  had  higher  sensitivity  for  BE
fusions than IE (79.16% vs 57.42% for FusionCatcher, 83.52% vs 65.35% for
MapSplice  and  95.89%  vs  84.79%  for  STAR-fusion).  However,  while
FusionCatcher and Mapsplice demonstrate higher average PPV in BE datasets
compared to IE (48.02% in BE fusions vs 44.07% in IE for FusionCatcher and
80.45% in BE fusions vs 76.50% in IE  for MapSplice), STAR-fusion presents
an opposite trend with an average PPV of 61.21% for IE fusions and 56.05%
for  BE  ones.  Chimerascan  on  the  other  hand  has  a  significantly  higher
sensitivity and PPV in IE fusions compared to BE fusions (average sensitivity
88.05% in IE fusions vs 53.25% in BE and average PPV of 53.88% in IE vs
44.71% in IE) (Figure 12,  Tables 7).
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Figure 12.  Fusion transcript  detection results  for  broken and intact  exon’s synthetic
datasets.
Boxplots show the distribution of Sensitivity (A, B) and PPV (C, D) in 24 broken exons (A, C)
and  24  intact  exons  (B,  D)  datasets  for  5  different  fusion  detection  softwares  (Defuse,
Chimerascan, STAR-fusion, MapSplice and FusionCatcher) and for the multi-tools approach
used by Fusion Validator.  
46
A
C D
B
Table 7. Distribution of Sensitivity, and PPV for fusion detected by 5 different softwares
on 48 synthetic datasets.
The probability of detecting a true fusion increased with the increment of the
sequencing  coverage  for  all  the  software,  except  for  STAR-fusion  and
Chimerascan. However, adding more reads to the simulated dataset tended to
inflate the number of false positive events, penalizing the PPV: This trend is
observed for all the fusion detection tools,  with the exception of Chimerascan,
in which the PPV appear to be constant for each sequencing coverage (Figure
13). 
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With  regards  to  the  performance  of  different  fusion  detection  software  for
datasets  of  different  read  length,  no  particular  improvement  in  term  of
sensitivity was found for the inspected tools, varying the sequence length under
fixed  coverage.  The  only  exception  is  represented  by  MapSplice  and
FusionCatcher,  that show a very poor performance in term of sensitivity for
datasets with reads of 50bp compared to the other lengths, particularly for IE
datasets. The impact of different read lengths on the number of extra calls and,
consequently, on the PPV depends on different software, breakpoint position
and coverage. Tools like Defuse, for example, tend to increase the number of
extra calls (and decrease the PPV), when the length of the reads decrease, in
both IE and BE samples. The same trend is observed in STAR-fusion for IE
samples and MapSplice for  BE samples  with  coverage  greater  than 100X
(Figure 13).  FusionCatcher,  on the other  hand,  shows a significantly  higher
PPV for shorter reads (50bp) and a progressive decrease of PPV when the
read length increase. No particular changes in PPV values for different read
length were found in Chimerascan.
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Figure 13.  Sensitivity and PPV distribution for  fusion transcript  detected by different
software  on  synthetic  datasets  of  different  coverage,  read  length  and  breakpoint
position.
Each row shows the results for 5 different fusion detection softwares (Defuse, Chimerascan,
STAR-fusion, MapSplice and FusionCatcher) and for the multi-tool approach used by Fusion
Validator. The 4 columns of the plot panel measure distribution of Sensitivity in broken and
intact exons and PPV in broken and intact exons database respectively. 
X-axis shows the trend of each distribution for different read coverage.
Read lengths are represented with different colors (red for 50bp, yellow for 75bp, green for
100bp and blue for 125bp).
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2.5.2 Fusion Validator maintains high accuracy across a range of sequence 
coverage and read lengths
Using  our  multi-tool  integrated  approach  implemented  in  Fusion  Validator,
chimeric  transcripts  detected  by  the  5  different  fusion  detection  algorithms
tested were merged into a single output. The multi-tools approach successfully
identified  an  average  of  99.58% of  the  fusions  for  the  IE  datasets  and an
average of  99.65% for  those in  the  BE group,  with  sensitivity  values  quite
constant across different read length and coverage datasets. Combining results
from different fusion finding algorithms, however, tends to increase the number
of  false  positive  events.  This  can  be  seen  from  the  PPV  distribution,  the
average values of which is lower than any single software evaluated (average
PPV 31.84% for IE  and 32.21% for BE fusions). Average PPV for the multi-tool
approach slightly decreases when the coverage increases for both BE and IE
datasets and slightly increases for read length increases in BE and IE datasets
with  coverage  greater  than  100X  (Table  8  and  Figure  13).  These  results
demonstrate  that  the  multi-tool  approach  adopted  by  Fusion  Validator  can
perform optimally for short reads and low coverage sequencing, as an increase
in terms of coverage and read length does not bring any benefit on number of
true fusions and extra calls detected.
The validation performed by Fusion Validator’s local realignment step, on fusion
transcripts detected by 5 different software, significantly reduced the number of
false positive fusion calls by half in all the simulated datasets, increasing the
average  PPV  to  66.01%  for  IE   and  64.56%  for  BE  subsamples,  and
maintaining a very high average sensitivity (94.79% and 96.75% for IE and BE
respectively), specificity (77.20% and 74.71% for IE and BE respectively) and
accuracy (82.78% and 81.75% for IE and BE respectively) (Table 9).
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Table 8. Distribution of Sensitivity, PPV and F-measure for Fusion Validator multi-tool
approach on 48 synthetic datasets.
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Table 9. Distribution of Sensitivity, PPV, Specificity, Accuracy and F-measure for Fusion 
Validator on 48 synthetic datasets.
When comparing the performance of Fusion Validator across subsamples of
different  coverage  and  read  length,  a  slight  increase  in  sensitivity  can  be
observed for each coverage increment in both IE and BE datasets, with 50bp
and  75bp  sequences  showing  higher  sensitivity  than  100bp  and  125bp
datasets.  This  difference is  due to  the method used to  subsample different
simulated  datasets,  as,  for  fixed  coverage,  an  increase  in  read  length
decreases the  total  number  of  reads in  the  dataset  and,  consequently,  the
number of candidate reads used by Fusion Validator to reconstruct the chimeric
transcript. The average sensitivity of Fusion Validator for shorter reads datasets
tends to converge to the one calculated for longer reads samples when there is
an  increase  in  coverage  (Figure   14).  In  contrast  to  what  happens  to  the
sensitivity, PPV and specificity for Fusion Validator tends to decrease slightly
for each increment of coverage, with longer sequences showing better PPV
and specificity than the shorter ones in both IE and BE datasets. Accuracy for
Fusion Validator appear to be constant across samples of different coverage,
as a result of a balance between the increase of TP events and sensitivity and
the decrease of TN and specificity related to the increase of read coverage.
The overall constant accuracy across different datasets makes Fusion Validator
an ideal  tool  with a good combination of sensitivity  and specificity,  that  can
perform extremely well also with short reads and coverage under 100X.
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Figure 14. Sensitivity, PPV, Specificity and Accuracy distribution for Fusion Validator on
synthetic datasets of different coverage, read length and breakpoint position.
The rows of the plot panel shows distribution of Sensitivity, PPV, Specificity and Accuracy. 
The columns of the panel measure distribution of different metrics in broken and intact exons
database respectively.
X-axis shows the trend of each distribution for different read coverage.
Read lengths are represented with different colors (red for 50bp, yellow for 75bp, green for
100bp and blue for 125bp).
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2.5.3 Fusion Validator demonstrates a better combination of sensitivity and 
precision compared to other fusion detection tools
Fusion Validator showed the best  average sensitivity among different fusion
detection tools in BE datasets and the second best after Defuse in IE subsets,
with only a 1.19% difference in average sensitivity (94.79% for Fusion Validator
vs 95.98% for  Defuse).  Fusion  Validator  was the second best  performer  in
terms of average PPV for both IE and BE dataset, after MapSplice (66.01% vs
76.50%  in  IE  datasets  and  64.50%  vs  80.45%  in  BE  datasets  for  Fusion
Validator and MapSplice respectively). However, MapSplice was able to detect
only an average of 65.35% of known fusions for IE subsets and an average of
83.52% for BE, with large range of variability among different coverage and
read length datasets (Figure 15A-B).
To compare the overall performance of Fusion Validator with results from other
fusion detection software, the F measure was calculated for each simulated
dataset  to summarize sensitivity  and PPV with  a single standardized index.
Distribution of F measure for different fusion finder tools showed that Fusion
Validator achieved the best performance for IE datasets,  with an average F
measure of 77.64%, and an average F measure of 77.31% for BE dataset, that
represent  the  second  best  score  after  MapSplice  (average  F  measure  for
MapSplice 81.51%) (Figure 15C-D). However, as reported above, despite the
high PPV, MapSplice’s performance in term of sensitivity is not in the same
range of Fusion Validator, with a probability of correctly identify a real fusion
that is 13.23% less than Fusion Validator.       
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Figure  15.  Fusion  detection  performance  evaluation  across  different  softwares  for
synthetic datasets.
The scatterplots display the relation between Sensitivity and PPV in broken exons (A) and
intact exons (B) databases for 5 different fusion detection tools (Defuse, Chimerascan, STAR-
fusion, MapSplice and FusionCatcher), multi-tools approach and Fusion Validator.
Colored  dots  point  out  the  average  Sensitivity  and  PPV  for  each  software,  while  95%
confidence intervals for Sensitivity and PPV is represented by colored ellipses. 
Boxplots show the distribution of F-measure in broken exons (C) and intact exons (D) datasets.
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2.6 Test set analysis
2.6.1 Fusion detection in breast cancer Cell Lines
To  assess  the  ability  of  Fusion  Validator  to  validate  real  known  fusion
transcripts from publicly available data sets, and evaluate its abilityto reduce
the number of candidate events detected by different fusion finder algorithms,
27 experimentally validated fusions from 4 different breast cancer cell lines (BT-
474, SK-BR-3, KPL-4, and MCF-7), identified by Edgren et al., were used as a
true positive set.
Results in table 10 show that none of the 5 fusion detection tools used (Defuse,
Chimerascan, STAR-fusion, MapSplice, FusionCatcher) identified all 27 known
fusions. The number of  true positive calls ranged from a minimum of 19/27
(70.37% sensitivity) in MapSplice to a maximum of 24/27 (88.89% sensitivity)
using  Chimerascan.  To  detect  all  27  experimentally  validated  chimeric
transcripts,  a combination of fusion calls from the 5 different  software were
performed by the first component of Fusion Validator. This step merged  5,494
fusion candidates, which were subsequently reduced to 3,190 after the normal
filtering, and finally further reduced to 1,134 after Fusion Validator’s final step.
This  represent  a  striking  79.36% reduction  in  the  number  of  false  positive
events (PPV for Fusion Validator 2.29% vs 0.47% for combined tools).
Strikingly, Fusion Validator was able to correctly validate 26 out of 27 known
fusions,  with  a sensitivity  significantly  higher  than all  the other fusion finder
algorithms  (sensitivity  96.30%).  Chimerascan  and  MapSplice  show  a  PPV
slightly higher to that of Fusion Validator (2.29% for Fusion Validator vs 2.88%
for  Chimerascan  and  2.97%  for  MapSplice)  but  these  tools  were  able  to
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correctly  identify  only  24/27  and  19/27  known  fusions  respectively.
FusionCatcher is the software with the higher PPV (43.14%), but it shows a
lack  in  sensitivity,  with  only  22/27  fusions  correctly  identified  (sensitivity
81.48%) (Table 11).
Table 11. Number of fusion transcript detected by 5 different softwares and filtered by
Fusion Validator on 4 BRCA Cell lines. 
Table 12. Average Sensitivity and PPV of 5 different fusion detection softwares, multi-
tool approach and Fusion Validator on 4 BRCA Cell lines. 
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2.6.2 Fusion Validator easily identified driver kinase fusions in TCGA pan 
cancer data 
To see if our method was able to correctly detect fusions from a larger cohort of
different tumour types and validate additional chimeric transcripts not found or
not reviewed in previous studies, we extended the analysis to 190 TCGA pan-
cancer samples carrying 195 validated recurrent kinase fusions (115 unique)
from Stransky et al..  This dataset was reanalyzed using a combination of 3
fusion detection tools (Defuse, Chimerascan and STAR-fusion) and processed
through the Fusion Validator pipeline.
 
The multi-tool  chimeric  transcript  detection  approach was able  to  select  an
average of 4904 fusion candidates per sample (95% confidence interval 4635-
5174), that were reduced to an average of 2945 (95% confidence interval 2755-
3136) and 983 (95% confidence interval 900-1067) per sample after normal
filtering  and local  realignment  validation  step  respectively,  with  a  significant
reduction  of  79.95%  of  the  candidate  fusions.  191  out  of  195  (97.95%)
recurrent validated fusions were also confirmed in silico by Fusion Validator,
with the four missing chimeric transcripts not found by any of the 3 fusion finder
algorithms used, and, therefore not been processed by the Fusion Validator
pipeline (list of fusions in Appendix A). One of the 4 missed transcripts is a
complex fusion affecting PDGFRA and overlapping genes FIP1L1 and LNX1 in
Brain Lower Grade Glioma sample TCGA-E1-A7YI-01A. For this sample STAR-
fusion  detected  a  chimeric  transcript  involving  FIP1L1,  but  with  a  different
partner CHIC2. The CHIC2 gene overlap with the longer isoform of PDGFRA,
which is  present  only  in  UCSC gene  models  (uc003haa.3)  and  not  on  the
Gencode19 annotation used for the analysis: The  FIP1L1-CHIC2 fusion can
thus be considered a product of different annotation databases rather than an
event missed by fusion finder algorithms (Figure 16).
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Figure 16. UCSC Genome Browser snapshot showing overlap between gene CHIC2 and
the longest isoform of PDGFRA on the fusion transcript breakpoint position.
Considering the list of non-recurring chimeric transcripts detected by Stransky
et al. in the 190 samples, 2/2 validated fusions, and 22/30 non reviewed events
were also confirmed by Fusion Validator (Appendix A). Fusion Validator was
also able to confirm and validate an additional 5384 kinase fusions removed by
the different filtering steps applied by Stransky et al., 791 of them recurrent in
more than 1 of the 190 analyzed samples.  This list includes  recurrent driver
fusions like FGFR3-TACC3 and RAF1-AGGF1, that were validated by Stransky
et al. In 15 (5 Bladder Urothelial Carcinoma, 3 Lung squamous cell carcinoma,
2 Glioblastoma multiforme, 2 Head and Neck squamous cell carcinoma, 2 Brain
Lower  Grade  Glioma  and  1  Kidney  renal  papillary  cell  carcinoma)  and  7
samples  respectively  (7  Thyroid  carcinoma)  and  were  confirmed  by  Fusion
Validator in additional 2 (2 Glioblastoma multiforme) and 1 samples (1 Thyroid
carcinoma) respectively.
Sorting the final annotated list of fusions for each sample by ranking score, in
descending order,  we found that  151 out  of  191 (79.06%)  recurrent  fusion
transcripts  validated  by  Fusion  Validator  were  classified  by  the  annotation
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module with the best ranking score, thus demonstrating a high probability of
being classified as driver fusions. Since Stransky et al. focused their analysis
only  on  kinase  fusions,  the  percentage  of  fusions  classified  with  the  best
ranking score by Fusion Validator  is affected by the presence of  no kinase
driver  fusions,  as,  for  example,  in  sample  TCGA-33-4587-01A,  where  the
highest annotation score is assigned to a non-kinase activating fusion between
PRSS33 and  CREBBP,  while the chimeric transcript involving  IGF2BP3 and
PRKCA,  validated  by  Stransky  et  al.,  has  only  the  second  best  score.
Considering  only  kinase  fusions,  the  percentage  of  chimeric  transcripts
classified with the best ranking score by Fusion Validator increases to 81.67%.
For some of the samples in Stransky’s dataset, more than one validated kinase
fusion  was  found.  For  example  in  sample  TCGA-CH-5737-01A,  both  the
experimental  validated  fusions,  KDM7A-BRAF  and  AGGF1-RAF1,  were  in
confirmed in silico by Fusion Validator and classified with the best and second
best annotation score, respectively.
   
To correctly evaluate the performance of Fusion Validator’s ranking score on
samples  with  multiple  recurrent  kinase  fusions,  the  percentage  of  validated
fusions in the top 3 and top 5 rank was considered as a more accurate metric.
180 out of 191 (94.24%) and 190 out of 191 (99.48%) validated kinase fusions
received  a  ranking  score  in  the  top  3  and  top  5  respectively  (Figure  17)
(Appendix A). This strong correlation between ranking score and probability of
a  fusion  to  be  validated,  support  the  idea  that,  to  quickly  identify  fusion
transcripts  for  downstream analysis,  it’s  sufficient  to  sort  a  Fusion  Validator
output by ranking score and select the top 3 validated candidates. In doing so,
one has a  ~95% sensitivity in detecting a real kinase driver fusion. 
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Figure  17.  Pie  chart  with  distribution  of  Fusion  Validator  ranking  positions  of  191
recurrent validated kinase fusions.
2.7 Discussion
In the last few years, the incorporation of RNA-Seq molecular tools into clinical
diagnostics  has turned out to be an attractive instrument to identify disease
and patient specific biomarkers that are tractable targets for therapy. The need
to  detect  driver  gene  fusions  on  large  scale  datasets  have  stimulated  a
remarkable effort to develop new bioinformatics algorithms for identifying gene
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fusions  from  sequencing  data,  each  of  them  showing  different  levels  of
sensitivity.  Meta caller or so called ‘ensemble approaches’ proposed in  the
literature are useful to explore a wide-ranging panel of potential real fusions,
but dramatically increase the number of false positive events. The choice of
proper standardized filtering steps that maximize sensitivity and specificity, and
the use of algorithms for  candidate fusion prioritization, is  crucial  to  quickly
identify  driver  oncogenic  fusions  for  downstream  analysis  and  wet-lab
validation.
To solve the main challenges in clinical validation of fusion transcripts coming
from NGS experiments, we developed Fusion Validator, an optimized pipeline
tool designed to collect thousands of fusion transcripts detected by different
fusion finder algorithms and to identify clinically relevant fusion genes, with a
significant  79.95%  reduction  of  the  number  of  candidates  that  need  to  be
subsequently assessed through experimental validation.
Fusion Validator recreates the chimeric transcript sequence around the fusion
breakpoint and  performs a number of filtering steps, including the removal of
read through transcripts and genes from user defined list of invalidated events,
local  realignment  of  normal  tissues  sequences  on  fusion  transcripts  and
flagging of fusions in homologous and repetitive regions around the breakpoint.
Validation of each fusion transcript  sequences is carried out through a local
realignment of reads around the fusion breakpoint and a combination of both a
de  novo assembly  and  a  seed and  extend  mapping  of  read  candidates  to
reconstruct the breakpoint. A ranking score based on annotation is assigned to
the final list of filtered and validated transcripts. Fusion Validator can work with
canonical  fusions  as  well  as  other  somatic  structural  changes  in  the
transcriptome,  like  exon  skips,  and  can  take  advantage  of  different  new
features  that  provide  major  accuracy  improvements  over  traditional  fusion
detection and prioritization algorithms:
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The combined  tool  approach  implemented by  Fusion  Validator,  can take  in
input lists of fusions from the most common fusion detection tools and easily
merge results,  by simply aggregating basic standard information like genes,
breakpoint  locations and strand orientations.  This  approach demonstrated a
highly significant increase in sensitivity for  both real and simulated datasets
analyzed  compared  to  other  fusion  detection  algorithms.  Moreover,  Fusion
Validator can extract additional fusion information not given by the majority of
fusion detection tools. Each fusion transcript sequence is retrieved using one
set of  rules,  independent  of  the software from which it  was selected,  in an
attempt to eliminate any bias related to different references and annotations.
Another  distinguishing  feature  of  Fusion  Validator  is  the  use  of  a  dynamic
normal filtering step, that realigns all of the control samples from human normal
tissues  against  every  putative  aberrant  junction,  instead  of  processing  the
tumour and normals separately: Comparing putative junctions against a multi-
tissue  dataset,  using  raw  reads,  was  demonstrated  to  be  the  most
comprehensive way of reducing false positives. The use of a dynamic blacklist,
to store normal chimeric transcripts detected by Fusion Validator, provides a big
advantage in term of computational costs, as candidate fusions that have been
found in normal tissues before are not re-processed, and in terms of specificity,
as the normal filter’s performance continues to improve as additional samples
are  processed.  Ultimately,  the  use  of  a  blacklist  has  allowed  us  to  quickly
discard more than a half of the initial fusions candidates. The local realignment
of tumour reads to reconstruct the chimeric transcript provides a robust and
reliable  validation  of  each  candidate  event,  since  reads  that  perfectly
encompass  the  breakpoint  are  selected  first,  and  then  reassembled  with
different  independent  methods  (de  novo  assembly  and  seed  and  extend
scaffold reconstruction). The use of a genomic realignment filter option ensures
an additional reduction of false positive events caused by alignment errors or
reads mapping on low complexity or homologous regions.  The final  ranking
score assigned by the annotation module of Fusion Validator to each chimeric
64
transcript  that  passed  the  filtering  steps,  can  be  used  by  clinicians  and
researchers to quickly identify events of interest for downstream analysis: It’s
sufficient  to  look  at  the  top  3  fusions  for  each  sample,  and  without  any
experimental  validation,  to  have  a 95%  probability  to  find  a  real  driver
oncogenic fusion. 
Fusion  Validator  performs well  in  terms of  overall  accuracy across  different
experimental conditions, showing an excellent combination of sensitivity and
specificity, even for low coverage and short reads sequencing. This advantage
leads to reducing the cost of sequencing per patient, since it has been shown
that a coverage increase does not bring particular advantage to the number of
fusions successfully detected, and lack in coverage can be easily compensated
by using additional fusion detection tools as input for Fusion Validator to retain
a high level of sensitivity. The characteristic of maintaining a very high accuracy
at reduced sequencing costs, make Fusion Validator an ideal diagnostic tool in
precision medicine research applied to oncology patients, where gene fusions
are critical as diagnostic and prognostic factors.
2.8 Software characteristics
Fusion Validator is implemented in Perl and Unix and It has been tested on a
Linux  high  performance  compute  cluster  (Centos  distribution  6.8)  with  job-
scheduling software Portable Batch System (PBS).
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Chapter 3: Direct transcriptional
consequences of somatic mutation in
cancer
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3.1 Introduction
3.1.1 Somatic mutations can amplify the transcriptional output in cancer cells.
Somatic  mutation  underpins  the  development  of  cancer,  and  most  solid
tumours have thousands to tens of thousands of point mutations, coupled with
tens to hundreds of genomic rearrangements and copy number changes2,53,54. 
Small  numbers  of  these,  known  as  ‘driver  mutations’,  dysregulate  the
fundamental  cellular  processes  involved  in  normal  tissue  homeostasis,  and
confer  a  selective advantage to  the clone.  A critical  point  is  that  Darwinian
selection acts on phenotype and so, for a somatic mutation to drive cancer, it
must manifest a phenotypic effect. Transcription is the primary conduit by which
changes in the genomic code are translated into cellular phenotype, with the
corollary that it  is a necessary criterion of driver mutations that they directly
induce a change in transcript  structure. Altered transcript  structure can take
many forms, including the creation of fusion genes by genomic rearrangement,
interference with RNA splicing at mutated splice sites, alteration of the codon
sequence for missense substitutions and over or under-expression of genes
through copy number alterations or mutation in regulatory regions.
Beyond  the  primary  and  direct  effects  of  somatic  mutation  on  transcript
structure, there may be a series of downstream, secondary alterations in the
transcriptome occurring as a consequence of the primary effect. Most studies
of the transcriptome in cancer, including those from large-scale efforts such as
TCGA45,55,  have  evaluated  these  second-order  effects,  concentrating
predominantly  on  the  magnitude  of  gene  expression  using  microarray
tecnologies56-58 or  RNA  sequencing59,60.  They  have  revealed  large-scale
disturbances  of  transcriptional  regulation  in  most  cancers,  with  expression
profiles for many hundreds of genes differing from profiles of normal cellular
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counterparts. Within a tumour type, similarities in transcriptional profiles across
individuals allow the disease to be sub-classified into several groups, many of
which have biological, therapeutic and prognostic significance. In some cases,
these changes can be correlated  with  underlying  driver  mutations,  such as
ERBB2  amplification  in  Breast  Cancer58 or  specific  fusion  genes  in  acute
myeloid leukaemia61. While these studies have concentrated on mRNA profiles,
similar  observations  are  beginning  to  emerge  from  studies  of  MicroRNA
transcription62,  long  non-coding  RNA  levels  and  even  expression  of
pseudogenes63. While it is a necessary criterion for a driver mutation to directly
induce modification of transcript structure, it is not sufficient. Many mutations
that do not confer selective advantage, so-called passenger mutations, will also
generate phenotypic consequences, but consequences of no benefit to the cell.
Initial studies correlating RNA-sequencing data with genomic change in cancer
have  reported  some  of  these  direct  effects,  especially  for  coding  point
mutations or canonical fusion transcripts59 but there has been little systematic
effort  to  describe,  measure  and  quantify  first-order  transcriptional
consequences across all classes of somatic mutation found in well-annotated
cancer genomes.
3.1.2 Transcriptional Amplification as target therapy
Transcriptional  amplification  is  a  phenomenon  by  which  certain  oncogenes
contribute to  tumour  progression  by increasing a cell’s  global  production  of
RNA  and,  consequently,  the  entire  transcriptome  of  a  cell  increases  in
expression.  Cancer  cells  have  been  shown  to  become  heavily  reliant  on
elevated  levels  of  transcriptional  activity,  making  them  highly  sensitive  to
targeted  therapies  that  selectively  inhibit  transcription.  For  this  reason
transcriptional  amplification represents a novel,  and demonstrably targetable
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feature of cancer,  where precision therapies often fail,  because cancer cells
have  the  unique ability  to  adapt  to  changing environmental  pressures,  and
targeting  oncogenic  pathways  can  ultimately  select  for  cancer  cell
subpopulations that have evolved to obsolesce those particular pathways for
survival.  However,  the  understanding  of  transcriptional  amplification’s
prevalence  and  its  implications  for  malignant  progression  is  still
underdeveloped.
The  second  sub-project  of  this  thesis  was  focused  on  developing  a
bioinformatics method to measure the transcriptional output of human primary
tumour cells,  using a validation set  of   nearly a thousand of TCGA Breast
Cancer  patients,  in  order  to  have  a  comprehensive  understanding  of
transcriptional amplification in cancer cell biology.
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3.2 Material and Methods
3.2.1 TCGA Breast Cancer dataset
Aligned  BAM files  for  980  breast  cancer  samples  with  both  RNA-Seq  and
exome sequencing were downloaded from CGHUB (https://cghub.ucsc.edu/)
using GeneTorrent.  PCR duplicates for both exome and transcriptome were
removed  using  SAMtools.  The  position  of  somatic  mutations,  in  MAF  file
format, and gene expression values (using the RSEM method) were obtained
from  https://tcga-data.nci.nih.gov/. Additional clinical covariates were obtained
from cBioPortal  (http://www.cbioportal.org/) (Figure 18). All putative mutations
were  re-annotated  using  Annovar  (release  2013Aug23)  and  all  potential
germline variants were removed (present in NCBI dbSNP Human build 142).
Finally, 70,071 exonic/splicing substitutions present in the 980 RNA-Seq and
WES paired samples were considered for further analysis. Mutations in the 5’
or 3’ UTRs were excluded.
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Figure 18. Schematic overview of information downloaded from TCGA dataset for 980
Breast Cancer samples (green  boxes) and extracted from starting raw data (light blue
boxes).
3.2.2 Analysis of variant allele fraction differences between the transcriptome 
and genome in TCGA data
A bioinformatcs software was developed to accurately measure the number of
bases  supporting  each  mutation  in  the  genome  (or  exome)  and  in  the
corresponding  transcriptome  for  each  of  the  70,071  somatic  mutations
selected. The tool parses the sequencing alignment file for both DNA and RNA
samples,  extracts  all  the  sequence  bases  aligning  in  each  of  the  selected
somatic  point  mutations and calculates the Variant  Allele  Fraction (VAF) for
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each position as the frequency of variant alleles in a given locus, using the
formulas 
                                
,where nVARdna is the number of variant calls for the specific base in the DNA
alignment,  nREFdna is the number of reference calls for the same base, and
nVARrna and nREFrna are  the  number  of  variant  calls  and the  number  of
reference  calls  for  the  specific  base  in  the  RNA alignment  respectively.  To
estimate  the  effect  of  somatic  mutations  on  transcription,  the  proportion  of
sequencing  reads  supporting  the  mutant  allele  in  the  transcriptome  was
compared to that expected from the genome. This proportion was measured as
the difference between VAF in the transcriptome and in the genome (VAFdifference
= VAFtranscriptome -  VAFgenome) (Figure 19). Mutated loci were considered as not
expressed, and therefore excluded from the analysis, if the total coverage was
less than five reads, or the number of reads supporting the mutated base was
less than five reads. The total number of somatic variants considered for further
analysis after filtering steps is 25,177 , corresponding to 955 patients (Figure
20).  Information  about  variant  allele  fraction  differences  and  percentage  of
expressed  mutations  were merged with clinical  data and gene expression
quantification. Linear regression was used to model the relationship between
the  amount  of  ESR1  expressed  by  a  tumor  and  the  VAF difference  of  its
mutations. Survival  data was analyzed using the Kaplan-Meier and log-rank
Mantle-Cox methods. The limit of significance for all analyses was defined as P
< .05. TCGA Breast Cancers were classified into known subtypes (Luminal B,
Luminal  A,  HER2-related  and  triple  negative)  by  immunohistochemistry
according to Blows et al63 (Figure 21).
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Figure 19. Example of somatic C -> T mutation in TP53 gene alignments for DNA (on the
top) and RNA (on the bottom). For both DNA and RNA Variant Allele Fraction is calculated as
the number of variants (base T in orange) divided by the number of total reads. Difference
between VAF in RNA and DNA is used as a measure of transcriptional amplification for the
specific mutation. Grey bars represent each aligned read and variant base T is highlighted in
red.  
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Figure 20. Transcriptional amplification analysis workflow for 980 TCGA DNA and RNA
sequencing  from  Breast  Cancer  patients.  980  samples  for  which  both  DNA and  RNA
sequencing was available were analyzed. PCR duplicates were removed from both DNA and
RNA alignments  and  variant  allele  fraction  for  each  coding  SNV   was  computed  in  both
datasets. The proportion of sequencing reads supporting the mutant allele in the transcriptome
compared to that expected from the genome was estimated as the difference between VAF in
RNA and DNA. 25,177 SNVs belonging to 955 samples were selected after filtering positions
not covered or not expressed in RNA. 
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Figure  21.  Classification  of  breast  cancer  subtypes  according  to  IHC marker  profile
(Figure from Blows et .al)64. Each Breast Cancer subtype is characterized by the expression
of immunohistochemistry markers Estrogen receptors (ER), Progesterone receptors (PR) and
Human epidermal grow factor receptor-2 (HER2)  
3.3 Results
3.3.1 On average  exonic point mutations are expressed to the level of would 
expect from their prevalence in the genome.
25,177 somatically acquired base substitutions in 955 breast cancer samples
were covered in both the genome and the transcriptome (>4 reads) and were
found to  be expressed (>4 variant reads present in the transcriptome). The
average percentage of mutations expressed in the  transcriptome is about 60%.
Variant allele fraction (VAF) in the genome and the transcriptome are strongly
positively correlated (Pearson's correlation coefficient =0.6439, p-value<0.0001
Figure 22).  To estimate the effect of  somatic mutations on transcription, the
proportion  of  sequencing  reads  supporting  the  mutant  allele  in  the
transcriptome  was  compared  to  that  expected  from  the  genome.  This
proportion was measured as the difference between VAF in the transcriptome
and in the genome.  
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Figure 22. Variant Allele Fraction comparison in RNA-Seq and DNA for all protein coding
mutations.  X  and  Y  axis  shows  the  distribution  of  VAF  in  genome  and  transcriptome
respectively. Each dot of the scatterplot represent a single nucleotide variant and is colored by
sample. Black regression line represent the theoretical condition of maximum linear correlation
between VAF in DNA and VAF in RNA 
There were some differences in the transcription levels of base substitutions
according to the predicted consequence on the protein. Silent, missense and
UTR  mutations  have  the  same  strong  correlation  between  variant  allele
fractions in the genome and transcriptome, whereas nonsense mutations have
a weaker relationship. Indeed, nonsense mutations had a significantly lower
expression  than  predicted  from  the  genome  compared  to  other  classes  of
mutation (p<0.0001).  Several reasons could explain the lower expression of
nonsense  mutations.  Nonsense-mediated  decay  could  selectively  target
transcripts  with  nonsense  mutations  for  degradation.  Nonsense-mediated
decay  depends  upon  the  cell  distinguishing  a  premature  termination  codon
from a proper termination codon. Generally, stop signals in the last exon are
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considered proper, whereas those appearing more than 50-55bp upstream of
the  last  exon-exon  junction,  and  therefore  upstream  of  the  exon-junction
complex,  are  more  likely  to  be  targeted  for  nonsense-mediated  decay  .
Another possible explanation for the low expression of nonsense mutations is
that they are tolerated only in genes not expressed in the cancer cells, those
occurring in important genes would be subject to negative selection.
To explore this possibility, the expression levels from the organoids of normal
breast epithelium for genes mutated in the cancer samples was compared. No
clear-cut differences across the mutation categories for whether the mutated
genes were found to be expressed in normal breast epithelial cells (Figure 23),
suggesting that  this reason does not explain the lower expression levels of
nonsense mutations. Therefore, it appears as if only nonsense mediated decay
explains the lower expression of these mutations.
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Figure23. Absence of negative selection in nonsense mutations. 
Comparison of  expression levels  from the organoids of  normal breast  epithelium for genes
mutated in the cancer samples. 
79
3.3.2 Expressed mutations are significantly inversely correlated to the Estrogen
receptor levels
The average VAF in the transcriptome relative to the genome is greater and
significantly different in estrogen receptor positive patients (0.12669) compared
to estrogen receptor negative ones (0.06353) (p-value <0.0001, Figure 24). The
average  VAF  difference  between  the  transcriptome  and  the  genome  is
significantly  negatively  correlated  with  the  expression  level  of  gene  that
encodes  the  estrogen  receptor,  ESR1  (Pearson's  correlation  =-0.2669,  p-
value<0.0001), and significantly  positively correlated with the percentage of
mutations  expressed  in  transcriptome  (Pearson's  correlation  =0.1074,  p-
value=0.0009).  The  percentage  of  mutations  expressed  is  also  significantly
positively  correlated  with  ESR1  gene  expression  (Pearson's
correlation=0.0725, p-value=0.0251) (Table 13). 
Figure 24. Variant allele fraction in transcriptome relative to genome distribution for ER
negative (red) and ER positive (light blue) samples.
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Table  13.  Pairwise  Pearson  correlation  for  VAF  difference,  ESR1  gene  expression,
number  of  mutations  and  percentage  of  mutation  expressed  in  955  Breast  Cancer
samples.
The  VAF  difference  between  the  transcriptome  and  the  genome  can  be
estimated with a linear discriminant function of 2 variables: ESR1 expression
and  percentage  of  mutation  expressed.  In  Figure  25,  if  ESR1  expression
decreases, the VAF difference increases proportionally and the percentage of
mutations expressed increase as well.  That is, tumours with high levels of ER
express fewer mutations than cancers with low ER. This relationship can be
formally modelled as: for every 1% decrease in ESR1 expression, 15 more
mutations are expressed in breast cancer.
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Figure  25  Regression  model  for  average  Variant  Allele  Fraction  difference  and
percentage of expressed mutations, stratified by ESR1 expression.
Expression of ESR1 gene is represented in log scale from lower (red) to higher expression
values (blue). VAF difference is directly proportional to the percentage of mutations expressed
and inversely proportional to ESR1 expression 
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3.3.3 Transcriptional amplification differs in the most common breast cancer 
subtypes
We  stratified  breast  cancer  patients  into  different  subgroups  by  their
immunohistochemistry  staining  for  estrogen,  progesterone  and  HER2
receptors.  The  distribution  of  percentage  of  mutation  expressed  and  VAF
difference between the transcriptome and the genome was compared for the
four main breast  cancer  subgroups:  Triple  Negative Breast  Cancer  (TNBC),
HER2  positive,  Luminal  A  and  Luminal  B.  The  VAF  difference  in  the
transcriptome  relative  to  the  genome,  as  well  as  percentage  of  mutations
expressed tends to increase if the breast cancer subgroups with better clinical
outcome (Luminal A/B) are compared to subgroups with the worst prognosis
(HER2 positive and TNBC). Average percentage of mutations expressed range
from 61.28% of the Luminal B subgroup to 70.31% of TNBC (Figure 26).
Breast cancer patients were divided in two groups according to a threshold of
0.045504 for VAF difference, selected as the value that maximizes the sum of
sensitivity and specificity in the ROC curve. Patients with high VAF difference
between the transcriptome and the genome had a better prognosis than the
ones with the low VAF difference group with median overall survival of 114 and
90.8 months, respectively. Survival curves computed using the Kaplan-Meier
method shows a statistically significant survival difference between high and
low VAF difference groups, with a 0.05 p-value for log rank Mantel-Cox test
(Figure 27).
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Figure 26. Variant Allele Fraction difference (violin plots on the top) and percentage of
mutated samples (histogram on the bottom) distribution according to  4  main Breast
Cancer subgroups (Luminal B in red, Luminal A in green, HER2 positive in light blue
and Triple Negative Breast Cancer in purple). 
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Figure 27. Overall Survival curve for Breast Cancer patients stratified by low (red) and
high (blue) Variant Allele Fraction difference.
3.4 Discussion
The disturbed transcriptional landscape of cancer cells results from three main
forces: (1) direct, primary consequences of somatic mutation; (2) co-ordinated,
secondary gene expression changes resulting from altered cellular signaling,
transcriptional  regulation  and  chromatin  landscape;  and  (3)  general  loss  of
transcriptional fidelity, manifesting as shorter 3’ UTRs , retained introns, trans-
splicing and so on.
  
This  sub-project  was  focused  on  dissecting  the  immediate  impact  that  the
repertoire  of  somatic  mutations  has  on  the  transcriptome in  breast  cancer,
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exploring  the  rules  that  govern  how the  transcriptional  machinery  interprets
somatic  mutation.  Integration  of  transcriptomic  with  genomic  can  determine
which mutations are expressed and their effect on gene expression profile.
An exhaustive bioinformatics tool for analyzing RNA sequencing data combined
with whole genome/exome sequencing was developed and applied to a huge
dataset of 980 breast  cancers. The software computes the proportion of reads
supporting  a given variant  in  the  DNA (VAF DNA),  that  is  reflective  of  that
variant’s  concentration within a sample,  and then models the transcriptional
output of human cancer cells ,by measuring the deviation in RNA allelic fraction
(VAF  DNA)  from  the  DNA allelic  fraction.  This  measure  was  called  VAF
difference.  
Using the VAF difference as a method to account for differences in tumor purity,
we  found  that  about  60%  of  Breast  Cancer  exonic  point  mutations  are
expressed and induce some transcriptional consequence, and a striking anti-
correlation between ER levels and the number of expressed mutations. That is,
tumors with high levels of ER express fewer mutations than cancers with low
ER. This relationship determined that, for every 1% decrease in ER expression,
15 more mutations are expressed. As a breast cancer loses estrogen receptor
expression,  and  becomes  more  transcriptionally  active,  it  is  more  likely  to
actually express its complement of somatic mutations. While speculative, this is
of  interest  to  researchers  in  the  field  of  immunotherapy,  since  somatic
mutations can act as neoantigens that could trigger host immune responses.
There  are  studies  reporting  strong  associations  between  the  number  of
neoantigens  and  response  to  immunotherapy,  and  these  data  suggest  that
such  mutations  are  more  likely  to  be  expressed  in  ER-negative  or  ER-low
tumors.
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Stratifying  Breast  Cancer  patients  by  clinical  factors,  we  found  that  the
difference  in  VAF  between  the  transcriptome  and  the  genome,  as  well  as
percentage of mutations expressed differs in the most common Breast Cancer
subgroups and can be used to predict better or poorer clinical outcome in terms
of overall survival. In fact, the VAF difference in the transcriptome relative to the
genome and the percentage of exonic mutations expressed tends to increase
their  values going from subtypes with better (Luminal A/B) to worst (TNBC)
prognosis. Breast cancer subgroups can be inferred using a model that include
data  from  the  genomic  and  transcriptomic  profile  of  the  patient  when
information  about  immunohistochemistry  for  the  Estrogen  Receptor,
Progesterone Receptor and HER2 are unavailable or uncertain.
Having developed a method to feasibly measure differences in transcriptional
amplification between individual cells on sporadic breast cancer, a well-studied
tumour  type, and having demonstrated that transcriptional amplification is a
distinguishing feature between known cancer subtypes and may correlate with
those subtype’s clinical prognosis, different future works can be developed from
this study. One of these includes a complete characterization of transcriptional
amplification process across thousands of different tumours, in order to predict
and  classify  different  cancer  subtypes  using  a  signature  based  on
transcriptional output measure from DNA and Rna sequencing. This signature
can help  clinicians to  identify  cancer  subtype diagnosis,  to  select  the  most
suitable treatment option and predict patient’s clinical outcome.
87
Chapter 4: Conclusions
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Two bioinformatics software for RNA sequencing analysis applied to precision
medicine oncology were developed:
The first,  Fusion  Validator  is  able  to  collect  thousands of  fusion  transcripts
detected by different fusion finder algorithm and discriminate real fusions from
false positive ones. The tool recreates the chimeric transcript sequence around
the fusion breakpoint and significantly reduces the number of fusion candidates
for validation, performing different filtering steps like local realignment of normal
tissues  sequences  on  fusion  transcripts,  de  novo and  seed  and  extend
realignment of tumour candidates reads, search for homologous and repetitive
regions around the breakpoint  and use of  a ranking score based on fusion
product annotation. 
Analysis of simulated synthetic showed an overall better performance of Fusion
Validator in terms of Sensitivity and PPV, when compared to 5 different fusion
detection  tools,  with  a  constant  F-measure  across  samples  of  different
coverage, read length and breakpoint positions. Fusion Validator was able to
successfully detect and 96.30% of the chimeric transcripts validated in literature
on  4  Breast  Cancer  Cell  lines  and 97.95% of  the  recurrent  kinase fusions
validated in 190 pan cancer samples, with a significant 79.95% reduction of
false positive events. 94.24% of the validated fusions were predicted by Fusion
Validator with a ranking score on the top 3.
Fusion Validator can be used as a very quick and efficient diagnostic tool for
KiCS  program to  increase  the  performance  in  detecting  driver  fusions  and
significantly reduce the number of false positives in particular disorders, where
gene fusions are critical as diagnostic and prognostic factors.
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The second software integrates transcriptomic with genomic data to measure
transcriptional  amplification  in  primary  tumours  and  to  determine  which
mutations are  expressed.  It  also  determine their  effect  on  gene expression
profile. The software measures the proportion of sequencing reads supporting
the mutant  allele  in  the transcriptome,  compared to  that  expected from the
genome as the Variant Allele Fraction in the transcriptome related the genome.
Analysis of 25177 somatic variants in 955 Breast Cancer samples showed that
60% of exonic point mutations are expressed and induce some transcriptional
consequence,  and  that  number  of  expressed  mutations  are  significantly
inversely  correlated  to  the  Estrogen Receptor  levels.  Variant  Allele  Fraction
differences between the transcriptome and genome, as well as percentage of
mutations expressed,  differs in the most common Breast  Cancer subgroups
and  can  be  used  as  a  diagnostic  tool  to  infer  tumour  subgroup  when
information  about  immunohistochemistry  for  the  Estrogen  Receptor,
Progesterone  Receptor  and  HER2  are  unavailable  or  uncertain,  or  as
prognostic tool to predict better or poorer clinical outcome.    
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Appendix A
List  of  kinase  fusion  transcripts  from  TCGA  pan-cancer  datasets
processed through the Fusion Validator pipeline.
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